Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (481-490 of 506) with videos related to

Pageof 51
Sort By:
The Journal of Clinical Investigation|March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcomeHouda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Cancer Discovery|December 19, 2013
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemiaRongqing Pan, Leah J Hogdal, Juliana M Benito, et al.
Nature Communications|November 20, 2020
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.
Journal of Hematology & Oncology|November 5, 2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Mingzhi Zhang, Zijun Y Xu-Monette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Oncotarget|October 22, 2021
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Cancer Cell|May 7, 2019
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell LethalityJo Ishizawa, Sarah F Zarabi, R Eric Davis, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
American Journal of Hematology|December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortalityAbhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Pageof 51

Showing results (481-490 of 506) with videos related to

Sort By:
Pageof 51
The Journal of Clinical Investigation|March 5, 2014
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcomeHouda Alachkar, Ramasamy Santhanam, Kati Maharry, et al.
Cancer Discovery|December 19, 2013
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemiaRongqing Pan, Leah J Hogdal, Juliana M Benito, et al.
Nature Communications|November 20, 2020
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.
Journal of Hematology & Oncology|November 5, 2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53Manman Deng, Mingzhi Zhang, Zijun Y Xu-Monette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Oncotarget|October 22, 2021
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201Joshua E Allen, C Leah B Kline, Varun V Prabhu, et al.
Cancer Cell|May 7, 2019
Mitochondrial ClpP-Mediated Proteolysis Induces Selective Cancer Cell LethalityJo Ishizawa, Sarah F Zarabi, R Eric Davis, et al.
Blood Cancer Journal|March 7, 2021
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisRashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Panagiotis Katsonis, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
American Journal of Hematology|December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortalityAbhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Pageof 51